Categories: News

Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress. The conference call and webcast have been rescheduled to a time after the release of the e-poster presentation at the EHA 2021 Virtual Congress. Details for the rescheduled conference call are as follows:

Conference call and webcast details:

Monday, June 14, 2021 @ 8:00 am ET

Investor domestic dial-in: 877-407-0784

Investor international dial-in: +1 201-689-8560

Conference ID: 13719675

Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell

Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com

Follow @GracellBio on LinkedIn

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com

Staff

Recent Posts

Robot End-Effector Market Is Expected To Reach US$13.76 Billion By 2031 With CAGR Of 14.5% | The Insight Partners

NEW YORK, Sept. 19, 2025 /PRNewswire/ -- According to a new comprehensive report from The…

3 hours ago

MX3 Diagnostics Achieves Customer Milestone: 300+ Elite Sports Organizations Worldwide

Professional and Collegiate Teams Trust MX3's Hydration Testing Technology AUSTIN, Texas, Sept. 19, 2025 /PRNewswire/…

3 hours ago

Acclinate Named to Inc. 5000 List of America’s Fastest-Growing Private Companies

BIRMINGHAM, Ala., Sept. 19, 2025 /PRNewswire/ -- Acclinate, the health equity company pioneering community-powered engagement…

3 hours ago

LabWare Launches Clinical Health Solution 5.06

Elevating Performance and Efficiency for Clinical and Public Health Labs WILMINGTON, Del., Sept. 19, 2025…

3 hours ago

FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy

PARAMUS, N.J., Sept. 19, 2025 /PRNewswire/ -- NS Pharma, Inc. announced today that the U.S.…

3 hours ago

Garmin celebrates global innovators and collaborations at 2025 Garmin Health Summit

Annual event recognizes top digital health solutions and connects international thought leaders OLATHE, Kan., Sept.…

3 hours ago